Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 4 Results of the RESORCE trial[41]
| Regorafenib (n = 379) | Placebo (n = 194) | HR, P-value | |
| OS (M, 95%CI) | 10.6 (9.1-12.1) | 7.8 (6.3-8.8) | HR 0.63 (95%CI 0.50-0.79) P < 0.0001 |
| PFS (M, 95%CI) | 3.1 (2.8-4.1) | 10.6 (1.4-1.6) | HR 0.46 (95%CI 0.37-0.56) P < 0.0001 |
| TTP (M, 95%CI) | 3.2 (2.9-4.2) | 10.6 (1.4-1.6) | HR 0.44 (95%CI 0.36-0.55) P < 0.0001 |
| Objective response(investigator assessed, mRECIST) | |||
| CR | 2 (1%) | 0 | |
| PR | 38 (10%) | 8 (4%) | |
| SD | 206 (54%) | 62 (32%) | |
| PD | 86 (23%) | 108 (56%) | |
| ORR | 40 (11%) | 8 (4%) | P = 0.0047 |
| DCR | 247 (65%) | 70 (36%) | P < 0.0001 |
- Citation: Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
- URL: https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i7.789